{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,30]],"date-time":"2026-07-30T09:56:57Z","timestamp":1785405417693,"version":"3.56.0"},"reference-count":177,"publisher":"Sociedade Brasileira de Pneumologia e Tisiologia","license":[{"start":{"date-parts":[[2026,6,22]],"date-time":"2026-06-22T00:00:00Z","timestamp":1782086400000},"content-version":"unspecified","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Respir Res Clin Pract"],"abstract":"<jats:p>Objective: Severe eosinophilic asthma (SEA) is often associated with chronic rhinosinusitis\nwith nasal polyps (CRSwNP) characterized by type 2\u2013driven eosinophilic inflammation.\nWe sought to investigate the effect of mepolizumab on relevant clinical, functional, and\ninflammatory endpoints in na\u00efve SEA patients with or without nasal polyps evaluated\nthrough induced sputum and followed for 12 months. Methods: We conducted an\nexploratory observational real-world cohort study including biologic-na\u00efve SEA patients\nwho initiated treatment with mepolizumab at an asthma referral center in Tradate, Italy.\nClinical, functional, and inflammatory parameters were assessed at baseline and after\n12 months. Induced sputum was used to evaluate airway inflammation. Patients were\nstratified by presence or absence of CRSwNP. Results: Forty patients were included,\n27\/40 (67.5%) had CRSwNP. After 12 months, significant reductions were observed in\nannual exacerbations (median, 2.0 vs. 0.0; adjusted p value [p-adj] &lt; 0.001), maintenance\noral corticosteroid use (5.0 vs. 0.0 mg; p-adj = 0.004), blood eosinophil count (543 vs. 55\ncells\/\u00b5L; p-adj &lt; 0.001), and sputum eosinophil % (39.0% vs. 1.3%; p = 0.004). Asthma\ncontrol and FEV1\n improved significantly. In patients with CRSwNP, sinonasal symptoms\nmarkedly improved (p-adj = 0.004). No post-treatment differences in airway eosinophilia\nwere detected between the groups. Overall, 77.5% achieved clinical remission in\naccordance with Severe Asthma Network Italy Delphi consensus criteria. Conclusions:\nMepolizumab provided substantial clinical, functional, and anti-inflammatory benefits in\nSEA, regardless of CRSwNP status. Despite higher baseline eosinophilia, patients with\nCRSwNP showed no clear differences in outcomes when compared with those without\nCRSwNP, supporting the concept of united airway disease. These findings highlight\nthe value of induced sputum as a noninvasive tool and support integrated, comorbiditydriven approaches in severe asthma management.<\/jats:p>","DOI":"10.36416\/1806-3756\/e20250422","type":"journal-article","created":{"date-parts":[[2026,6,23]],"date-time":"2026-06-23T19:11:30Z","timestamp":1782241890000},"page":"e20250422","source":"Crossref","is-referenced-by-count":0,"title":["The role of airway inflammation: effectiveness of mepolizumab in asthma with and without chronic rhinosinusitis and nasal polyps"],"prefix":"10.36416","author":[{"given":"Francesco","family":"Ardesi","sequence":"first","affiliation":[{"id":[{"id":"https:\/\/ror.org\/00mc77d93","id-type":"ROR","asserted-by":"publisher"}],"name":"Istituti Clinici Scientifici Maugeri"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marco","family":"Vanett","sequence":"additional","affiliation":[{"id":[{"id":"https:\/\/ror.org\/00mc77d93","id-type":"ROR","asserted-by":"publisher"}],"name":"Istituti Clinici Scientifici Maugeri"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rosella","family":"Centis","sequence":"additional","affiliation":[{"id":[{"id":"https:\/\/ror.org\/04tfzc498","id-type":"ROR","asserted-by":"publisher"}],"name":"Istituti di Ricovero e Cura a Carattere Scientifico"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Martina","family":"Zappa","sequence":"additional","affiliation":[{"id":[{"id":"https:\/\/ror.org\/04tfzc498","id-type":"ROR","asserted-by":"publisher"}],"name":"Istituti di Ricovero e Cura a Carattere Scientifico"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Patrizia","family":"Pignatti","sequence":"additional","affiliation":[{"id":[{"id":"https:\/\/ror.org\/04tfzc498","id-type":"ROR","asserted-by":"publisher"}],"name":"Istituti di Ricovero e Cura a Carattere Scientifico"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Enrico","family":"Heffler","sequence":"additional","affiliation":[{"id":[{"id":"https:\/\/ror.org\/04ehykb85","id-type":"ROR","asserted-by":"publisher"}],"name":"Institute of Biomedical Technologies"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stefania","family":"Gallo","sequence":"additional","affiliation":[{"id":[{"id":"https:\/\/ror.org\/02s6h0431","id-type":"ROR","asserted-by":"publisher"}],"name":"Ospedale di Circolo e Fondazione Macchi"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giulia","family":"Franzini","sequence":"additional","affiliation":[{"id":[{"id":"https:\/\/ror.org\/04tfzc498","id-type":"ROR","asserted-by":"publisher"}],"name":"Istituti di Ricovero e Cura a Carattere Scientifico"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Denise","family":"Rossato Silva","sequence":"additional","affiliation":[{"id":[{"id":"https:\/\/ror.org\/041yk2d64","id-type":"ROR","asserted-by":"publisher"}],"name":"Universidade Federal do Rio Grande do Sul"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giovanni","family":"Battista Migliori","sequence":"additional","affiliation":[{"id":[{"id":"https:\/\/ror.org\/04tfzc498","id-type":"ROR","asserted-by":"publisher"}],"name":"Istituti di Ricovero e Cura a Carattere Scientifico"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Antonio","family":"Spanevello","sequence":"additional","affiliation":[{"id":[{"id":"https:\/\/ror.org\/04tfzc498","id-type":"ROR","asserted-by":"publisher"}],"name":"Istituti di Ricovero e Cura a Carattere Scientifico"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dina","family":"Visca","sequence":"additional","affiliation":[{"id":[{"id":"https:\/\/ror.org\/04tfzc498","id-type":"ROR","asserted-by":"publisher"}],"name":"Istituti di Ricovero e Cura a Carattere Scientifico"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"22288","published-online":{"date-parts":[[2026,6,22]]},"reference":[{"key":"ref0","unstructured":"1. Global Initiative for Asthma. Global strategy for asthma management"},{"key":"ref1","unstructured":"and prevention, 2025; Updated May 2025. Bethesda: GINA; 2025."},{"key":"ref2","unstructured":"2. Brusselle GG, Koppelman GH. Biologic Therapies for Severe Asthma."},{"key":"ref3","doi-asserted-by":"crossref","unstructured":"N Engl J Med. 2022;386(2):157-171. https:\/\/doi.org\/10.1056\/","DOI":"10.1056\/NEJMra2032506"},{"key":"ref4","unstructured":"NEJMra2032506"},{"key":"ref5","unstructured":"3. Porsbjerg C, Menzies-Gow A. Co-morbidities in severe asthma:"},{"key":"ref6","doi-asserted-by":"crossref","unstructured":"Clinical impact and management. Respirology. 2017;22(4):651-661.","DOI":"10.1111\/resp.13026"},{"key":"ref7","doi-asserted-by":"crossref","unstructured":"https:\/\/doi.org\/10.1111\/resp.13026","DOI":"10.1111\/resp.13026"},{"key":"ref8","unstructured":"4. Visca D, Ardesi F, Zappa M, Pignatti P, Grossi S, Vanetti M, et al."},{"key":"ref9","unstructured":"Asthma and hypertension: the role of airway inflammation. Front"},{"key":"ref10","unstructured":"Med (Lausanne). 2024;11:1451625. https:\/\/doi.org\/10.3389\/"},{"key":"ref11","unstructured":"fmed.2024.1451625"},{"key":"ref12","unstructured":"5. Canonica GW, Malvezzi L, Blasi F, Paggiaro P, Mantero M, Senna"},{"key":"ref13","unstructured":"G, et al. Chronic rhinosinusitis with nasal polyps impact in severe"},{"key":"ref14","unstructured":"asthma patients: Evidences from the Severe Asthma Network"},{"key":"ref15","unstructured":"Italy (SANI) registry. Respir Med. 2020;166:105947. https:\/\/doi."},{"key":"ref16","unstructured":"org\/10.1016\/j.rmed.2020.105947"},{"key":"ref17","unstructured":"6. Siddiqui S, Bachert C, Bjermer L, Buchheit KM, Castro M, Qin Y, et"},{"key":"ref18","unstructured":"al. Eosinophils and tissue remodeling: Relevance to airway disease. J"},{"key":"ref19","doi-asserted-by":"crossref","unstructured":"Allergy Clin Immunol. 2023;152(4):841-857. https:\/\/doi.org\/10.1016\/j.","DOI":"10.1016\/j.jaci.2023.06.005"},{"key":"ref20","unstructured":"jaci.2023.06.005"},{"key":"ref21","unstructured":"7. Pavord ID, Korn S, Howarth P, Bleecker ER, Buhl R, Keene ON, et al."},{"key":"ref22","unstructured":"Mepolizumab for severe eosinophilic asthma (DREAM): a multicentre,"},{"key":"ref23","doi-asserted-by":"crossref","unstructured":"double-blind, placebo-controlled trial. Lancet. 2012;380(9842):651-9.","DOI":"10.1016\/S0140-6736(12)60988-X"},{"key":"ref24","doi-asserted-by":"crossref","unstructured":"https:\/\/doi.org\/10.1016\/S0140-6736(12)60988-X","DOI":"10.1016\/S0140-6736(12)60988-X"},{"key":"ref25","unstructured":"8. Haldar P, Brightling CE, Hargadon B, Gupta S, Monteiro W, Sousa"},{"key":"ref26","unstructured":"A, et al. Mepolizumab and exacerbations of refractory eosinophilic"},{"key":"ref27","doi-asserted-by":"crossref","unstructured":"asthma. N Engl J Med. 2009;360(10):973-84. https:\/\/doi.org\/10.1056\/","DOI":"10.1056\/NEJMoa0808991"},{"key":"ref28","unstructured":"9. Nair P, Pizzichini MM, Kjarsgaard M, Inman MD, Efthimiadis A,"},{"key":"ref29","unstructured":"Pizzichini E, et al. Mepolizumab for prednisone-dependent asthma"},{"key":"ref30","doi-asserted-by":"crossref","unstructured":"with sputum eosinophilia. N Engl J Med. 2009;360(10):985-93.","DOI":"10.1056\/NEJMoa0805435"},{"key":"ref31","doi-asserted-by":"crossref","unstructured":"https:\/\/doi.org\/10.1056\/NEJMoa0805435","DOI":"10.1056\/NEJMoa0805435"},{"key":"ref32","unstructured":"10. Chupp GL, Bradford ES, Albers FC, Bratton DJ, Wang-Jairaj J, Nelsen"},{"key":"ref33","unstructured":"LM, et al. Efficacy of mepolizumab add-on therapy on health-related"},{"key":"ref34","unstructured":"quality of life and markers of asthma control in severe eosinophilic"},{"key":"ref35","unstructured":"asthma (MUSCA): a randomised, double-blind, placebo-controlled,"},{"key":"ref36","unstructured":"parallel-group, multicentre, phase 3b trial. Lancet Respir Med."},{"key":"ref37","doi-asserted-by":"crossref","unstructured":"2017;5(5):390-400. https:\/\/doi.org\/10.1016\/S2213-2600(17)30125-X","DOI":"10.1016\/S2213-2600(17)30125-X"},{"key":"ref38","unstructured":"11. Bravo-Guti\u00e9rrez FJ, Miralles-L\u00f3pez JC, Valverde-Molina J,"},{"key":"ref39","unstructured":"Alemany Franc\u00e9s ML, And\u00fajar-Espinosa R, Castilla-Mart\u00ednez"},{"key":"ref40","unstructured":"M, et al. Effectiveness of Mepolizumab in Patients with Severe"},{"key":"ref41","unstructured":"Eosinophilic Asthma with\/without Nasal Polyposis: A Real-Life"},{"key":"ref42","unstructured":"Study. Int Arch Allergy Immunol. 2024;185(3):253-259. https:\/\/doi."},{"key":"ref43","unstructured":"org\/10.1159\/000534902"},{"key":"ref44","unstructured":"12. Schleich F, Loukides S, Chaudhuri R, Leuppi JD, Heffler E, Domingo"},{"key":"ref45","unstructured":"C, et al. Mepolizumab Effectiveness in Severe Asthma With\/Without"},{"key":"ref46","unstructured":"Chronic Rhinosinusitis With Nasal Polyps: Real-World Pooled"},{"key":"ref47","doi-asserted-by":"crossref","unstructured":"Analysis. Allergy. 2025;80(9):2557-2571. https:\/\/doi.org\/10.1111\/","DOI":"10.1111\/all.16618"},{"key":"ref48","unstructured":"all.16618"},{"key":"ref49","unstructured":"13. Efthimiadis A, Spanevello A, Hamid Q, Kelly MM, Linden M,"},{"key":"ref50","unstructured":"Louis R, et al. Methods of sputum processing for cell counts,"},{"key":"ref51","unstructured":"immunocytochemistry and in situ hybridisation. Eur Respir J Suppl."},{"key":"ref52","doi-asserted-by":"crossref","unstructured":"2002;37:19s-23s. https:\/\/doi.org\/10.1183\/09031936.02.00001902","DOI":"10.1183\/09031936.02.00001902"},{"key":"ref53","unstructured":"14. Domvri K, Tsiouprou I, Bakakos P, Steiropoulos P, Katsoulis K,"},{"key":"ref54","unstructured":"Kostikas K, et al. Effect of mepolizumab in airway remodeling"},{"key":"ref55","unstructured":"in patients with late-onset severe asthma with an eosinophilic"},{"key":"ref56","doi-asserted-by":"crossref","unstructured":"phenotype. J Allergy Clin Immunol. 2025;155(2):425-435. https:\/\/doi.","DOI":"10.1016\/j.jaci.2024.10.024"},{"key":"ref57","unstructured":"org\/10.1016\/j.jaci.2024.10.024"},{"key":"ref58","unstructured":"15. Gerday S, Graff S, Moermans C, Guissard F, Paulus V, Henket M, et"},{"key":"ref59","unstructured":"al. Super-responders to anti-IL-5\/anti-IL-5R are characterised by high"},{"key":"ref60","doi-asserted-by":"crossref","unstructured":"sputum eosinophil counts at baseline. Thorax. 2023;78:(11):1138-","DOI":"10.1136\/thorax-2022-219781"},{"key":"ref61","doi-asserted-by":"crossref","unstructured":"1141. https:\/\/doi.org\/10.1136\/thorax-2022-219781","DOI":"10.1136\/thorax-2022-219781"},{"key":"ref62","unstructured":"16. Moermans C, Brion C, Bock G, Graff S, Gerday S, Nekoee H, et al."},{"key":"ref63","unstructured":"Sputum Type 2 Markers Could Predict Remission in Severe Asthma"},{"key":"ref64","doi-asserted-by":"crossref","unstructured":"Treated With Anti-IL-5. Chest. 2023;163(6):1368-1379. https:\/\/doi.","DOI":"10.1016\/j.chest.2023.01.037"},{"key":"ref65","unstructured":"org\/10.1016\/j.chest.2023.01.037"},{"key":"ref66","unstructured":"17. \u0160oki\u0107 MK, Rijavec M, Koro\u0161ec P, Bidovec-Stojkovi\u010d U, Kern I, Vantur"},{"key":"ref67","doi-asserted-by":"crossref","unstructured":"R, et al. Heterogeneous Response of Airway Eosinophilia to AntiIL-5 Biologics in Severe Asthma Patients. J Pers Med. 2022;12(1):70.","DOI":"10.3390\/jpm12010070"},{"key":"ref68","doi-asserted-by":"crossref","unstructured":"https:\/\/doi.org\/10.3390\/jpm12010070","DOI":"10.3390\/jpm12010070"},{"key":"ref69","unstructured":"18. Crimi C, Campisi R, Nolasco S, Cacopardo G, Intravaia R, Porto M, et"},{"key":"ref70","unstructured":"al. Mepolizumab effectiveness in patients with severe eosinophilic"},{"key":"ref71","unstructured":"asthma and co-presence of bronchiectasis: A real-world retrospective"},{"key":"ref72","doi-asserted-by":"crossref","unstructured":"pilot study. Respir Med. 2021;185:106491. https:\/\/doi.org\/10.1016\/j.","DOI":"10.1016\/j.rmed.2021.106491"},{"key":"ref73","unstructured":"rmed.2021.106491"},{"key":"ref74","unstructured":"19. Detoraki A, Tremante E, D\u2019Amato M, Calabrese C, Casella C,"},{"key":"ref75","unstructured":"Maniscalco M, et al. Mepolizumab improves sino-nasal symptoms"},{"key":"ref76","unstructured":"and asthma control in severe eosinophilic asthma patients with"},{"key":"ref77","unstructured":"chronic rhinosinusitis and nasal polyps: a 12-month real-life study."},{"key":"ref78","unstructured":"Ther Adv Respir Dis. 2021;15:17534666211009398. https:\/\/doi."},{"key":"ref79","unstructured":"org\/10.1177\/17534666211009398"},{"key":"ref80","unstructured":"20. McDowell PJ, Diver S, Yang F, Borg C, Busby J, Brown V, et al."},{"key":"ref81","unstructured":"The inflammatory profile of exacerbations in patients with severe"},{"key":"ref82","unstructured":"refractory eosinophilic asthma receiving mepolizumab (the"},{"key":"ref83","unstructured":"MEX study): a prospective observational study. Lancet Respir"},{"key":"ref84","unstructured":"Med. 2021;9(10):1174-1184. https:\/\/doi.org\/10.1016\/S2213-"},{"key":"ref85","unstructured":"2600(21)00004-7"},{"key":"ref86","unstructured":"21. Mukherjee M, Forero DF, Tran S, Boulay ME, Bertrand M, Bhalla"},{"key":"ref87","unstructured":"A, et al. Suboptimal treatment response to anti-IL-5 monoclonal"},{"key":"ref88","unstructured":"antibodies in severe eosinophilic asthmatics with airway"},{"key":"ref89","doi-asserted-by":"crossref","unstructured":"autoimmune phenomena. Eur Respir J. 2020;56(4):2000117. https:\/\/","DOI":"10.1183\/13993003.00117-2020"},{"key":"ref90","unstructured":"doi.org\/10.1183\/13993003.00117-2020"},{"key":"ref91","unstructured":"22. Schleich F, Graff S, Nekoee H, Moermans C, Henket M, Sanchez C,"},{"key":"ref92","unstructured":"et al. Real-word experience with mepolizumab: Does it deliver what"},{"key":"ref93","doi-asserted-by":"crossref","unstructured":"it has promised? Clin Exp Allergy. 2020;50(6):687-695. https:\/\/doi.","DOI":"10.1111\/cea.13601"},{"key":"ref94","unstructured":"org\/10.1111\/cea.13601"},{"key":"ref95","unstructured":"23. Dweik RA, Boggs PB, Erzurum SC, Irvin CG, Leigh MW, Lundberg"},{"key":"ref96","unstructured":"JO, et al; An official ATS clinical practice guideline: interpretation"},{"key":"ref97","unstructured":"of exhaled nitric oxide levels (FENO) for clinical applications. Am J"},{"key":"ref98","unstructured":"Respir Crit Care Med. 2011;184(5):602-15. https:\/\/doi.org\/10.1164\/"},{"key":"ref99","unstructured":"rccm.9120-11ST"},{"key":"ref100","unstructured":"24. Canonica GW, Blasi F, Carpagnano GE, Guida G, Heffler E, Paggiaro"},{"key":"ref101","unstructured":"P, et al. Severe Asthma Network Italy Definition of Clinical Remission"},{"key":"ref102","unstructured":"in Severe Asthma: A Delphi Consensus. J Allergy Clin Immunol Pract."},{"key":"ref103","doi-asserted-by":"crossref","unstructured":"2023;11(12):3629-3637. https:\/\/doi.org\/10.1016\/j.jaip.2023.07.041","DOI":"10.1016\/j.jaip.2023.07.041"},{"key":"ref104","unstructured":"25. Harrison T, Canonica GW, Chupp G, Lee J, Schleich F, Welte T,"},{"key":"ref105","unstructured":"et al. Real-world mepolizumab in the prospective severe asthma"},{"key":"ref106","doi-asserted-by":"crossref","unstructured":"REALITI-A study: initial analysis. Eur Respir J. 2020;56(4):2000151.","DOI":"10.1183\/13993003.00151-2020"},{"key":"ref107","doi-asserted-by":"crossref","unstructured":"https:\/\/doi.org\/10.1183\/13993003.00151-2020","DOI":"10.1183\/13993003.00151-2020"},{"key":"ref108","unstructured":"26. Harvey ES, Langton D, Katelaris C, Stevens S, Farah CS, Gillman A, et"},{"key":"ref109","unstructured":"al. Mepolizumab effectiveness and identification of super-responders"},{"key":"ref110","doi-asserted-by":"crossref","unstructured":"in severe asthma. Eur Respir J. 2020;55(5):1902420. https:\/\/doi.","DOI":"10.1183\/13993003.02420-2019"},{"key":"ref111","unstructured":"org\/10.1183\/13993003.02420-2019"},{"key":"ref112","unstructured":"27. Moore WC, Stach-Klysh A, Corbridge T, Packnett E, McMorrow D,"},{"key":"ref113","unstructured":"Richards M, et al. Real-world mepolizumab treatment in patients with"},{"key":"ref114","unstructured":"severe asthma decreased exacerbations, oral corticosteroid use, and"},{"key":"ref115","unstructured":"healthcare resource utilization and costs over 4 years: a retrospective"},{"key":"ref116","doi-asserted-by":"crossref","unstructured":"analysis. J Asthma. 2025;62(6):984-996. https:\/\/doi.org\/10.1080\/027","DOI":"10.1080\/02770903.2025.2450640"},{"key":"ref117","unstructured":"70903.2025.2450640"},{"key":"ref118","unstructured":"28. Crimi C, Nolasco S, Noto A, Maglio A, Quaranta VN, Di Bona D,"},{"key":"ref119","unstructured":"et al. Long-Term Clinical and Sustained REMIssion in Severe"},{"key":"ref120","unstructured":"Eosinophilic Asthma Treated With Mepolizumab: The REMI-M"},{"key":"ref121","doi-asserted-by":"crossref","unstructured":"Study. J Allergy Clin Immunol Pract. 2024;12(12):3315-3327. https:\/\/","DOI":"10.1109\/ACCESS.2024.3349410"},{"key":"ref122","unstructured":"doi.org\/10.1016\/j.jaip.2024.08.033"},{"key":"ref123","unstructured":"29. Lee JK, Pollard SJ, Liu MC, Schleich F, Pelaia G, Almonacid C, et"},{"key":"ref124","unstructured":"al. Mepolizumab real-world effectiveness in severe asthma with"},{"key":"ref125","unstructured":"an eosinophilic phenotype and overlapping severe allergic asthma."},{"key":"ref126","unstructured":"Ann Allergy Asthma Immunol. 2025;135(1):37-46. https:\/\/doi."},{"key":"ref127","unstructured":"org\/10.1016\/j.anai.2025.01.002"},{"key":"ref128","unstructured":"30. Enr\u00edquez-Rodr\u00edguez AI, Hermida Valverde T, Romero \u00c1lvarez P, L\u00f3pezGonz\u00e1lez FJ, Gull\u00f3n Blanco JA, Exp\u00f3sito Villegas AR, et al. Results in"},{"key":"ref129","unstructured":"clinical practice in the treatment of severe eosinophilic asthma with"},{"key":"ref130","doi-asserted-by":"crossref","unstructured":"mepolizumab: a real-life study. J Asthma. 2022;59(5):1005-1011.","DOI":"10.1080\/02770903.2021.1897835"},{"key":"ref131","doi-asserted-by":"crossref","unstructured":"https:\/\/doi.org\/10.1080\/02770903.2021.1897835","DOI":"10.1080\/02770903.2021.1897835"},{"key":"ref132","unstructured":"31. H\u00e5kansson K, Thomsen SF, Konge L, Mortensen J, Backer V,"},{"key":"ref133","unstructured":"von Buchwald C. A comparative and descriptive study of asthma"},{"key":"ref134","unstructured":"in chronic rhinosinusitis with nasal polyps. Am J Rhinol Allergy."},{"key":"ref135","doi-asserted-by":"crossref","unstructured":"2014;28(5):383-7. https:\/\/doi.org\/10.2500\/ajra.2014.28.4076","DOI":"10.2500\/ajra.2014.28.4076"},{"key":"ref136","unstructured":"32. Visca D, Ardesi F, Zappa M, Grossi S, Pignatti P, Vanetti M, et al. The"},{"key":"ref137","unstructured":"effect of benralizumab on inflammation in severe asthma: a real-life"},{"key":"ref138","unstructured":"analysis. Ther Adv Respir Dis. 2024;18:17534666241304685. https:\/\/"},{"key":"ref139","unstructured":"doi.org\/10.1177\/17534666241304685"},{"key":"ref140","unstructured":"33. Carpagnano GE, Portacci A, Nolasco S, Detoraki A, Vatrella A,"},{"key":"ref141","unstructured":"Calabrese C, et al. Features of severe asthma response to antiIL5\/IL5r therapies: identikit of clinical remission. Front Immunol."},{"key":"ref142","doi-asserted-by":"crossref","unstructured":"2024;15:1343362. https:\/\/doi.org\/10.3389\/fimmu.2024.1343362","DOI":"10.3389\/fimmu.2024.1343362"},{"key":"ref143","unstructured":"34. Pavord I, Gardiner F, Heaney LG, Domingo C, Price RG, Pullan A,"},{"key":"ref144","unstructured":"et al. Remission outcomes in severe eosinophilic asthma with"},{"key":"ref145","unstructured":"mepolizumab therapy: Analysis of the REDES study. Front Immunol."},{"key":"ref146","doi-asserted-by":"crossref","unstructured":"2023;14:1150162. https:\/\/doi.org\/10.3389\/fimmu.2023.1150162","DOI":"10.3389\/fimmu.2023.1150162"},{"key":"ref147","unstructured":"35. Papaioannou AI, Kallieri M, Zervas E, Fouka E, Porpodis K, Hadji"},{"key":"ref148","unstructured":"Mitrova M, et al. Clinical remission in patients with severe"},{"key":"ref149","unstructured":"eosinophilic asthma treated with mepolizumab: A. Allergy Asthma"},{"key":"ref150","doi-asserted-by":"crossref","unstructured":"Proc. 2025;46(1):45-51. https:\/\/doi.org\/10.2500\/aap.2025.46.240084","DOI":"10.1089\/gen.45.09.17"},{"key":"ref151","unstructured":"36. Bilodeau L, Boulay ME, Prince P, Boisvert P, Boulet LP. Comparative"},{"key":"ref152","unstructured":"clinical and airway inflammatory features of asthmatics with or"},{"key":"ref153","doi-asserted-by":"crossref","unstructured":"without polyps. Rhinology 2010;48(4):420-5. https:\/\/doi.org\/10.4193\/","DOI":"10.4193\/Rhino09.095"},{"key":"ref154","unstructured":"Rhino09.095"},{"key":"ref155","unstructured":"37. Holguin F, Cardet JC, Chung KF, Diver S, Ferreira DS, Fitzpatrick"},{"key":"ref156","unstructured":"A, et al. Management of severe asthma: a European Respiratory"},{"key":"ref157","unstructured":"Society\/American Thoracic Society guideline. Eur Respir J."},{"key":"ref158","doi-asserted-by":"crossref","unstructured":"2020;55(1):1900588. https:\/\/doi.org\/10.1183\/13993003.00588-2019","DOI":"10.1183\/13993003.00588-2019"},{"key":"ref159","unstructured":"38. Bachert C, Brusselle G, Castillo Vizuete JA, D\u00e1vila I, Laudien M,"},{"key":"ref160","unstructured":"Seccia V, et al. Consensus from European experts on severe"},{"key":"ref161","unstructured":"eosinophilic asthma and chronic rhinosinusitis with nasal polyps:"},{"key":"ref162","unstructured":"Results from the OverSEA Delphi study. J Allergy Clin Immunol Glob."},{"key":"ref163","doi-asserted-by":"crossref","unstructured":"2025;4(4):100529. https:\/\/doi.org\/10.1016\/j.jacig.2025.100529","DOI":"10.1016\/j.jacig.2025.100529"},{"key":"ref164","unstructured":"39. Han JK, Bachert C, Fokkens W, Desrosiers M, Wagenmann M,"},{"key":"ref165","unstructured":"Lee SE, et al. Mepolizumab for chronic rhinosinusitis with nasal"},{"key":"ref166","unstructured":"polyps (SYNAPSE): a randomised, double-blind, placebo-controlled,"},{"key":"ref167","unstructured":"phase 3 trial. Lancet Respir Med. 2021;9(10):1141-1153. https:\/\/doi."},{"key":"ref168","unstructured":"org\/10.1016\/S2213-2600(21)00097-7"},{"key":"ref169","unstructured":"40. Cavaliere C, Loperfido A, Ciofalo A, Di Michele L, Begvarfaj E,"},{"key":"ref170","unstructured":"Bellocchi G, et al. Real-Life Evidence of Mepolizumab Treatment in"},{"key":"ref171","unstructured":"Chronic Rhinosinusitis with Nasal Polyps: A Multicentric Study. J Clin"},{"key":"ref172","doi-asserted-by":"crossref","unstructured":"Med. 2024;13(12):3525. https:\/\/doi.org\/10.3390\/jcm13123575","DOI":"10.3390\/jcm13123575"},{"key":"ref173","unstructured":"41. Matucci A, Accinno M, Maggiore G, Brugnoli B, Vivarelli E, Cosmi L,"},{"key":"ref174","unstructured":"et al. Mepolizumab Reduces Inflammatory Eosinophils in Nasal Polyp"},{"key":"ref175","unstructured":"Tissue and Restores Histological Alterations. J Investig Allergol Clin"},{"key":"ref176","doi-asserted-by":"crossref","unstructured":"Immunol. 2025 Jul 4:0. https:\/\/doi.org\/10.18176\/jiaci.1095","DOI":"10.18176\/jiaci.1095"}],"container-title":["Respiratory Research &amp; Clinical Practice"],"original-title":[],"link":[{"URL":"https:\/\/www.ithenticate.com\/","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,23]],"date-time":"2026-06-23T19:13:17Z","timestamp":1782241997000},"score":1,"resource":{"primary":{"URL":"https:\/\/rrcpjournal.org\/article\/the-role-of-airway-inflammation-effectiveness-of-mepolizumab-in-asthma-with-and-without-chronic-rhinosinusitis-and-nasal-polyps\/"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6,22]]},"references-count":177,"URL":"https:\/\/doi.org\/10.36416\/1806-3756\/e20250422","relation":{},"ISSN":["3086-3910"],"issn-type":[{"value":"3086-3910","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,6,22]]},"article-number":"2025-0422"}}